Regulatory status: AOD-9604 is not an approved human medicinal product in the EU or the USA (FDA NDI rejection 2014)
Concurrent administration of the two peptides is thus believed to have more potent healing effects, with research suggesting a synergistic effect to accelerate the migration of fibroblasts and immune system cells to sites of injury [8, 9, 11]
Product quality varies dramatically in the peptide market
Primary applications: wound healing (closure kinetics, collagen organization, tensile strength), tendon and ligament regeneration (Achilles transection, biomechanical testing), gastroprotection (NSAID protection, mucosal barrier, fistula healing), angiogenesis (HUVEC tube formation, VEGF expression, CAM assays), neuroprotection (gut-brain axis, neuroinflammatory reduction), and inflammation studies (cytokine modulation, ERK1/2 pathway)
Such solutions should be discarded rather than used, as activity is likely compromised